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to 0.2%, 0.2% to 0.3%, and 0.5%, respectively.1-3 
Individuals with inherited deficiencies of natural 
anticoagulants have an increased risk of venous 
thromboembolism (VTE), a disease whose man‑
agement is still challenging and requires ongoing 
research and clinical studies.4,5
INTRODUCTION The deficiencies of natural an‑
ticoagulants such as antithrombin (AT), protein 
C (PC), and protein S (PS) are inherited in most 
of the cases in an autosomal dominant pattern 
with variable penetrance. In the general Europe‑
an population, they have a frequency of 0.02% 
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ABSTRACT
INTRODUCTION Inherited deficiencies of natural anticoagulants such as antithrombin (AT; gene: SERPINC1), 
protein C (PC; PROC), and protein S (PS; PROS1), with the prevalence in the general European population 
of 0.02% to 0.17%, 0.2% to 0.3%, and 0.5%, respectively, are associated with increased risk of throm‑
boembolic events. Only a few case reports of Polish deficient patients with known causal mutations 
have been published so far.
OBJECTIVES The aim of the study was to characterize the frequency of SERPINC1, PROC, and PROS1 
mutations and their thromboembolic manifestations in patients with AT, PC, or PS deficiencies, inhabit‑
ing southern Poland.
PATIENTS AND METHODS Ninety unrelated patients (mean [SD] age, 40.1 [13.2] years) with AT (n = 35), 
PC (n = 28), or PS (n = 27) deficiencies, with a history of venous 73 (81%) or arterial 17 (19%) throm‑
boembolism, were screened for mutations using the Sanger sequencing or multiplex ligation ‑dependent 
probe amplification.
RESULTS Twenty mutations (29%) described here were new, mostly in the SERPINC1 and PROC genes. 
Missense mutations accounted for 84% of all mutations in the PROC gene and approximately 50% of 
those in the SERPINC1 and PROS1 genes. In all 3 genes, the ratio of nonsense and splice‑site mutations 
was 8% to 31% and 8% to 23%, respectively. The mutation detection rate was 90% for AT or PC when 
anticoagulant activity was below 70%, while for the PROS1 gene, the rate reached 80% at the free PS 
levels below 40%.
CONCLUSIONS To our knowledge, this is the largest cohort of Polish patients deficient in natural anti‑
coagulants and evaluated for the causal genetic background. Several new Polish detrimental mutations 
were detected, mostly in AT‑ and PC ‑deficient patients.
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January 2013 and December 2016. Of the ini‑
tially enrolled subjects, 10 were ineligible ow‑
ing to incomplete clinical and laboratory data 
(n = 7) or patient refusal (n = 3); thus, 90 pa‑
tients with AT (n = 35), PC (n = 28), and PS (n 
= 27) deficiencies were available for the purpose 
of the present study. All patients were inhabit‑
ants of southern Poland, mainly the Lesser Po‑
land (Małopolska) region.
The diagnosis of deep vein thrombosis (DVT) 
was established on the basis of a positive finding 
of color duplex sonography (the visualization of 
an intraluminal thrombus in the calf, popliteal, 
femoral, or iliac vein). The diagnosis of pulmo‑
nary embolism (PE) was based on the presence 
of typical symptoms and positive results of com‑
puted tomography (CT) pulmonary angiography.
A VTE episode was defined as unprovoked (id‑
iopathic) if the patient had no history of can‑
cer, surgery requiring general anesthesia, major 
trauma, a plaster cast or hospitalization within 
the last month, or pregnancy or delivery within 
the last 3 months. A proximal DVT was defined 
as thrombosis in the popliteal veins, including 
the trifurcation, femoral, or iliac veins.
The diagnosis of ischemic stroke was based 
on clinical symptoms according to the World 
Health Organization definition (http://www.
who.int/medicines/areas/priority_medicines/
BP6_6Stroke.pdf?ua=1) and brain imaging, usu‑
ally noncontrast CT. The diagnosis of myocardial 
infarction was based on the 2012 European Soci‑
ety of Cardiology criteria.21
The diagnosis of portal, splenic, and subclavian 
vein thrombosis was based on positive findings 
on a color duplex scan. In more complicated cas‑
es, CT angiography or magnetic resonance imag‑
ing was needed. The diagnosis of central retinal 
vein occlusion was based on typical clinical symp‑
toms (abrupt unilateral vision deterioration) and 
typical appearance of the eye fundus.
The diagnosis of femoral and brachial artery 
thrombosis was established on the basis of clin‑
ical symptoms of acute extremity ischemia and 
visualization of artery stenosis by color duplex 
scan sonography or by digital subtraction ultra‑
sound. The diagnosis of mesenteric artery throm‑
bosis was based on clinical symptoms of acute in‑
testinal ischemia and positive results of CT an‑
giography. The diagnosis of cerebral venous si‑
nus thrombosis was established by visualizing si‑
nus stenosis on magnetic resonance angiography.
The exclusion criteria were previous or current 
diagnosis of liver disease, cancer, pregnancy, and 
blood sampling at acute thrombotic event.
The Ethical Committee of Jagiellonian Univer‑
sity Medical College approved the study, and all 
90 participants provided their written informed 
consent.
Sample collection Blood samples were drawn 
from an antecubital vein into tubes containing 
citrate anticoagulant (9:1 of 0.106 M sodium ci‑
trate), centrifuged at 2.500 g at a temperature of 
A meta ‑analysis of case ‑control and cohort 
studies has shown that AT ‑deficient individu‑
als have a higher risk of the first VTE (odds ratio 
[OR], 16.3; 95% CI, 9.9–26.7) than those with PC 
(OR, 7.1; 95% CI, 3.2–17.5) or PS (OR, 5.4; 95% 
CI, 2.7–10.7) deficiency.6 In patients after the first 
incident of VTE, the prevalence of AT, PC, and 
PS deficiencies is estimated at 0.5% to 4.9%, 3%, 
and 2% to 12%, respectively.2,3,7 Evidence linking 
natural anticoagulant deficiencies with arterial 
thromboembolism, mostly ischemic stroke, is con‑
flicting and largely derived from case reports.2,8,9
AT  is the  main endogenous anticoagulant 
serpin (serine ‑protease inhibitor) that pri‑
marily inactivates thrombin and activated fac‑
tor (F) X. The gene encoding AT (SERPINC1) is 
located on chromosome 1q25.1 and consists 
of 7 exons and 6 introns spanning 13,574 bp 
(ENSG00 000 117 601).10 PC and PS are vita‑
min K ‑dependent glycoproteins. PC is a precur‑
sor of the serine protease, activated protein C 
(APC). Its proteolytic activation by thrombin oc‑
curs on the surface of endothelial cells and in‑
volves thrombomodulin and endothelial PC re‑
ceptor (EPCR). In the presence of PS, phospho‑
lipids, and calcium, APC inactivates activated FV 
and FVIII by their cleavage at the specific argi‑
nine residues.11 Plasma PS is in 60% noncova‑
lently complexed with the complement 4b ‑bind‑
ing protein (C4BP), while the remaining 40% cir‑
culates free.12 Both forms of PS serve as cofactors 
of APC but free PS is more potent.13
PC is encoded by PROC, a gene located on 
the long arm of chromosome 2q14. PROC is ap‑
proximately 10 842 bp long (ENSG00000115718) 
and comprises 9 exons separated by 8 introns.14 
The  PS gene (PROS1) is in turn located near 
the centromere of chromosome 3q11.2, spans 
101058 bp (ENSR00 001 368 680), and consists 
of 15 exons and 14 introns.15
The  mutation profiles of all the  3 genes, 
SERPINC1, PROC, and PROS1, are similar with 
the highest prevalence for missense mutations 
(63%–78%), followed by nonsense mutations 
(7%–11%), splice ‑site mutations (7%–13%), small 
deletions (1%–8%), small insertions/duplications 
(1%–4%), and large deletions (3%–6%).16
Thus far, the genetic deficiency of AT has been 
reported in 18 Polish families from Warsaw.17 
To the best of our knowledge, we report here 
on the largest cohort of patients from Poland, 
the country with over 38 million inhabitants, with 
the deficiency of natural anticoagulants, evaluat‑
ed for the causal genetic background. Previous‑
ly, we were the first to publish individual Polish 
cases genetically confirmed for AT,18 PC,19 and 
PS20 deficiencies.
PATIENTS AND METHODS Patients A total of 
100 unrelated patients with a personal history of 
thromboembolic events (n = 89), positive family 
history (n = 4), or obstetric complications (n = 7) 
in association with reduced AT, PC, or PS lev‑
els were enrolled in the current study between 
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Intolerant From Tolerant tool (http://sift.jcvi.org) 
integrated into Alamut Visual v2.3.6 software ap‑
plication (http://www.interactive ‑biosoftware.
com/alamut ‑visual/); a structure ‑based meth‑
od, Polymorphism Phenotyping v2 (PolyPhen ‑2, 
http://genetics.bwh.harvard.edu/pph); and 
the splicing prediction module of Alamut Visual, 
which uses the Human Splicing Finder v3.0 (HSF; 
http://www.umd.be/HSF/) algorithms.
Statistical analysis The distributions of quantita‑
tive variables were analyzed by the Shapiro–Wilk 
test. Normally distributed variables were com‑
pared using 1 ‑way analysis of variance (ANOVA) 
or the t test and were presented as mean (SD). 
Variables deviating from normal distribution 
were analyzed by the Kruskal–Wallis ANOVA or 
Mann–Whitney test and were presented as medi‑
an (interquartile range) if not otherwise indicated. 
Qualitative parameters were analyzed by the Pear‑
son χ2 or 2 ‑tailed Fisher exact test. Pairwise cor‑
relations were calculated using the Pearson coef‑
ficient on variables approximated to the normal 
distribution if required. A P value of less than 0.05 
was considered significant. Statistical calculations 
were performed using STATISTICA Version 10.0 
(StatSoft, Inc., Tulsa, Oklahoma, United States).
RESULTS The mean (SD) age of 90 participants 
with natural anticoagulant deficiencies was 40.1 
(13.2) years. Forty ‑seven patients (52.2%) were 
male. The mean (SD) age at the first VTE event 
was 35.6 (12.4) years. Thirty ‑one patients (34%) 
experienced a provoked VTE event, mostly de‑
spite pharmacological thromboprophylaxis. These 
patients were younger than those with an unpro‑
voked VTE (mean [SD] age, 32.2 [2.2] years vs 
44.3 [1.8] years; P = 0.02). Thirty ‑four patients 
(38%) had a positive family history of VTE.
Of the 90 patients enrolled, 65 (72%) carried 
genetic defects. Twenty mutations (29%) detect‑
ed in the current study have been reported for 
the first time, according to the comparison with 
the HGMD® database records. All new mutations 
were probably damaging and disease ‑causing as 
suggested by the in silico analysis.
Antithrombin deficiency The main characteristics 
of the AT ‑deficient cohort (n = 35) are shown in 
TABLE 1. The mean (SD) age was 43.0 (13.9) years, 
and 20 patients (57%) were male. The mean (SD) 
age at the first VTE event was 37.1 (14.1) years. 
The mean (SD) AT activity was 57.8% (9.3%) (less 
than 75% in all participants), and the median 
(IQR) AT antigen level was 0.16 g/l (0.15–0.22 g/l). 
Type I AT deficiency was detected in 19 patients 
(54.3%) and type II—in 11 patients (31.4%). In 
the remaining 5 patients (14.3%), the type of 
AT deficiency could not be determined due to 
incomplete laboratory data.
Antigen levels correlated with age of the first 
VTE event (r = 0.6; P = 0.002). Patients with type I 
AT deficiency were younger when they had experi‑
enced the first VTE event compared with patients 
18ºC to 22ºC for 20 minutes and processed imme‑
diately or stored in aliquots at –80ºC until analy‑
sis. Whole blood samples for DNA isolation were 
drawn into EDTA ‑K3 collection tubes and stored 
in aliquots at –80ºC until processing.
Laboratory tests The antigen levels and activi‑
ties of AT, PC, and PS were measured using estab‑
lished commercial assays after temporary with‑
drawal of vitamin K antagonists (for at least 10 
days)22 or oral novel anticoagulants (for at least 
24 hours).23
Antithrombin AT activity was measured using 
an assay based on FXa inhibition (INNOVANCE™ 
ATIII, Siemens Healthcare Diagnostics, Marburg, 
Germany) or thrombin ‑inhibition assays (Sie‑
mens Healthcare Diagnostics); the reference 
range for both was from 83% to 118%. AT an‑
tigen was determined nephelometrically (Sie‑
mens Healthcare Diagnostics; reference range, 
0.19–0.31 g/l). AT deficiency was classified as de‑
scribed previously.10,24
Protein C Plasma PC activity was quantified us‑
ing a chromogenic assay (HemosIL Protein C In‑
strumentation Laboratory, Milan, Italy or Beri‑
chrom Protein C, Siemens Healthcare Diagnos‑
tics), and PC antigen was measured by an enzyme‑
‑linked immunosorbent assay (Asserachrom 
Protein C, Diagnostica Stago, Asnieres, France) 
(reference range for all, 70%–140%). PC deficien‑
cy was classified as described previously.25
Protein S Free PS levels were measured using an 
immunoturbidimetric assay (HemosIL Free Pro‑
tein S; reference range for women, 55%–124%; ref‑
erence range for men, 74%–146% or INNOVANCE® 
Free PS Ag, Siemens Healthcare Diagnostic; ref‑
erence range for women, 60%–114%; reference 
range for men, 67%–139%). Total PS levels were 
assessed using Asserachrom Kit (Diagnostica St‑
ago; reference range, 75%–140%). PS deficiency 
was classified as previously described.25
Genetic analysis DNA was extracted from whole 
blood or a buffy coat according to the manufac‑
turer’s protocol, using Gene MATRIX Quick Blood 
DNA Purification Kit (Eurex, Gdańsk, Poland) and 
stored at –80ºC until analysis.
The  SERPINC1 (NM_000 488.3), PROC 
(NM_000 312.3), and PROS1 (NM_000 313.3) 
genes were analyzed as previously described.26-28 
For all samples with no causative point mutation 
identified, screening for large deletion/insertion 
was performed by multiplex ligation‑dependent 
probe amplification (SALSA MLPA kit for P227 
SerpinC1; P265 ‑PROC and P112 ‑A2 PROS1; MRC‑
‑Holland, Amsterdam, the Netherlands).
The analysis of a congenital disorder of glyco‑
sylation was performed as described previously.29
In silico analysis Each novel sequence variation 
was subjected to in silico analyses with a Sorting 
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PROC mutations Of the 28 patients with PC 
deficiency, 25 individuals had the mutation in 
the PROC gene, with a mutation detection rate 
of 89.3%.
Missense mutations occurred in 21 patients 
(84%), while nonsense and splice ‑site mutations 
in 2 patients each (8% for both). No gross PROC 
gene rearrangements were observed.
The detected mutations were mainly located 
in exon 9 (9 patients), exon 5 (5 patients), and 
in exon 7 (4 patients), which comprised 72% of 
the patients. Eight mutations (32%) have been 
reported here for the first time (TABLE 2).
Venous and arterial thrombosis The most com‑
mon thrombotic manifestation was isolated DVT 
(n = 10; 36%) or combined with PE (n = 9; 32%). 
Isolated PE was not found. One patient (3.6%) 
suffered from DVT and superficial vein thrombo‑
sis. Among atypical VTE, portal vein thrombosis 
(n = 1; 3.6%) and cerebral venous sinus thrombo‑
sis (n = 1; 3.6%) were observed. One woman ex‑
perienced 3 miscarriages (3.6%).
Arterial thrombosis occurred in 5 patients 
(18%) and included 2 myocardial infarctions, 2 
strokes, and brachial arterial embolism. Three 
subjects were asymptomatic but had a positive 
family history (TABLE 2).
Protein S deficiency The main characteristics 
of the PS ‑deficient cohort are shown in TABLE 3. 
The mean (SD) patient age was 38.2 (13.1) years. 
Ten patients (37%) were male. The first VTE event 
occurred at the mean (SD) age of 34.0 (9.4) years.
The  mean (SD) free PS levels were 37.0% 
(14.7%) and the mean (SD) total PS antigen was 
62.7% (18.0%). Fourteen patients (52.5%) had 
type I and 11 patients (40.1%) had type III PS 
deficiency. In 2 patients (7.4%), the type of PS 
deficiency could not be determined owing to in‑
complete laboratory data or variations in total 
PS levels.
Patients with idiopathic VTE had lower free PS 
levels than those with provoked VTE (mean [SD], 
27.1% [4.0%] vs 41.6% [4.0%]; P = 0.02).
PROS1 mutations Of the 27 patients with PROS1 
deficiency, 14 individuals had the PROS1 gene mu‑
tation with a mutation detection rate of 52%. If 
the cutoff value for free PS levels was above 40%, 
the mutation detection rate reached 77%.
Missense mutations were observed in 6 pa‑
tients (46%); nonsense mutations, in 4 patients 
(31%); and splice ‑site mutations, in 3 patients 
(23%). One deletion of exons 1 to 12 was found. 
The  detected mutations were located across 
the whole PROS1 gene. Three mutations (21%) 
have been reported here for the first time (TABLE 3).
Venous and arterial thrombosis The most com‑
mon thrombotic manifestation was isolated DVT 
(n = 15; 55.7%). DVT combined with PE was ob‑
served in 3 patients (11.1%), and isolated PE—in 
1 patient (3.7%). One event of cerebral venous 
with type II AT deficiency (mean [SD] age, 32.2 
[3.2] years vs 45.7 [4.3] years; P = 0.02).
SERPINC1 mutations Of the 35 patients with 
AT deficiency, 26 individuals had a mutation in 
the SERPINC1 gene, with a mutation detection 
rate of 74%. Glycosylation disorders with muta‑
tion in the phosphomannomutase 2 gene (PMM2) 
were detected in 3 patients.
Missense mutations represented the most fre‑
quent causal genetic variant type and were identi‑
fied in 15 patients (57.7%), followed by nonsense 
mutations in 4 patients (15.4%), splice ‑site mu‑
tations in 3 patients (11.5%), large deletions in 2 
patients (7.8%), and small deletion and large du‑
plication (1 patient [3.8%] each). In half of the pa‑
tients (50%), mutations were located mainly in 
exon 2 (9 patients) or exon 7 (4 patients).
Eight (31%) mutations were reported here for 
the first time (TABLE 1). The whole spectrum of mu‑
tations was present in patients with type I AT defi‑
ciency, while in patients with type II AT deficiency, 
only the missense variants were found. Patients 
with missense mutations tended to have high‑
er AT antigen expression than individuals with 
other types of causal genetic variants (0.21 g/l 
vs 0.15 g/l, P = 0.06).
Venous and arterial thrombosis The most com‑
mon thrombotic manifestation was isolated 
DVT (n = 14; 40%) or combined with PE (n = 13; 
37%). Isolated PE was present only in 2 patients. 
Moreover, we observed patients with portal vein 
thrombosis (n = 2; 6%), subclavian vein thrombo‑
sis (n = 1; 3%), splenic vein thrombosis and tes‑
tis ischemia (n = 1; 3%), and central retinal vein 
occlusion (n = 1; 3%) (TABLE 1).
Arterial thromboembolic events occurred in 
5 patients (14%) and comprised 3 cerebral isch‑
emic strokes, 1 myocardial infarction (with recur‑
rence), and 1 superior mesenteric artery throm‑
bosis combined with portal vein thrombosis. One 
individual was asymptomatic but had a positive 
family history.
Protein C deficiency The main characteristics 
of the PC ‑deficient patients are shown in TABLE 2. 
The mean (SD) age of the patients was 38.3 (13.4) 
years. Sixteen patients (57%) were male. The first 
VTE event occurred at a mean (SD) age of 35.0 
(12.6) years.
The mean (SD) PC activity was 51.1% (12.9%), 
and the mean (SD) total PC was 63.4% (25.9%). 
Thirteen patients (46.4%) had type I PC deficiency, 
and 2 individuals (7.2%)—type II. In 13 patients 
(46.4%), the type of PC deficiency could not be 
determined owing to incomplete laboratory data.
As expected, PC activity was positively corre‑
lated with age (r = 0.38; P <0.05). Patients who 
experienced an idiopathic VTE were older than 
those with a provoked VTE (mean [SD] age, 40.8 
[3.4] years vs 30.8 [3.6] years; P = 0.05) and had 
higher PC activity levels (mean [SD], 57.9% [3.5%] 
vs 42.8% [3.7%]; P = 0.008).
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hemostatic proteins, especially in situations as‑
sociated with increased thrombotic risk, such as 
pregnancy or infection.30,31 In the current study, 
only a patient carrying the p.Ala118Pro vari‑
ant had 2 DVT events in the postpartum period. 
The proband’s daughter inherited this mutation 
and so far remains asymptomatic.
Another new variant is an intronic c.625 ‑2A>G 
mutation affecting splicing by disturbing the ac‑
ceptor sequence of intron 3. This mutation is as‑
sociated in our patient with type I AT deficien‑
cy and was also detected in the proband’s father, 
suffering from DVT. In turn, the next novel vari‑
ant, the p.Thr433Ser mutation, affects a residue 
which, although not conserved in serpins, is lo‑
cated at the first strand of C β ‑sheet and may thus 
affect protein stability.
We also detected 1 compound heterozygote 
within the SERPINC1 gene comprising the nov‑
el p.Ser69Cys variant and previously described 
as p.Ser82Asn mutation.32 The p.Ser69Cys vari‑
ant affects helix A, potentially influencing pro‑
tein stability. However, the p.Ser82Asn mutation, 
responsible for creating a new N ‑glycosylation 
site associated with disturbances in peptide fold‑
ing ultimately leading to no protein secretion,32 
seems to play a more important role. In patients 
in whom no point mutations were found, 2 new 
large gene rearrangements were detected: a du‑
plication of exon 6 and a deletion of exons 2 to 5.
The majority of the newly detected PROC gene 
mutations, including p.Cys387Tyr, p.Val434Ala, 
and p.Leu320Pro, cluster in exon 9, within the re‑
gion encoding a catalytic domain. These vari‑
ants may potentially affect binding of the sub‑
strate.33 Moreover, in the  missense variant 
at position 387, cysteine is replaced by tyrosine, 
which may be important for disulfide bond for‑
mation, associated with protein stabilization. In 
turn, the p.Cys64Tyr variant of the PROC gene 
is located in the γ ‑carboxyglutamic domain with‑
in the PC structure. This domain is implicated 
in interactions of PC with its cofactors PS and 
EPCR for inactivation of FVa and FVIIIa.34 The p.
Cys64Tyr variant eliminates cysteine residues, 
which might result in aberrant protein multi‑
merization or creation of the high ‑molecular‑
‑weight protein complex and impaired protein 
secretion.33,35 A similar mutation in the same 
codon but with a different amino acid change 
(p.Cys64Gly) has been reported by Kuismanen 
et al35 in a family from Finland, with a history 
of thrombosis and type I PC deficiency. The next 
new p.Cys175Arg variant within the PROC gene 
is located in the epidermal growth factor (EGF)‑2 
domain and might affect PC stability.33
Another novel mutation, p.Gln226*, is locat‑
ed in the serine ‑protease domain and may yield 
a truncated protein product. It has been found 
that amino acids at position 225–235 of the PC 
serine ‑protease domain play an important role in 
the interaction between the PC and the throm‑
bin–thrombomodulin complex through a calcium‑
‑binding mechanism.36 Two other missense 
sinus thrombosis (3.7%) and four miscarriages 
(14.8%) were noted.
Arterial thrombosis was found in 7 patients 
(26%), including 7 strokes, 2 of which occurred 
after myocardial infarction (TABLE 3).
Mutation detection rate AT activity levels ranged 
between 38% and 67% in patients with a detected 
SERPINC1 gene mutation and glycosylation dis‑
orders, and between 49% and 77.5% in subjects 
without the mutation. In individuals with AT ac‑
tivity above 70%, no mutations were found, while 
in those with AT activity below 70%, the muta‑
tion detection rate was 90%.
Similarly, patients with a mutation in the PROC 
gene showed PC activity between 19% and 67%. 
In 3 patients without the mutation, PC activi‑
ty levels ranged from 18% to 53%. For PC activ‑
ities close to the normal range (70%), the muta‑
tion detection rate was above 90%.
Patients with a mutation within the PROS1 
gene had the PS activity levels of 8% to 53%, and 
those without the mutation—of 37% to 59%. For 
free PS levels below 40%, the mutation detection 
rate was 77%, and for free PS levels below 35%, 
the rate was 100%.
DISCUSSION To the best of our knowledge, this 
is the first large and comprehensive study analyz‑
ing the genetic background of deficiencies in nat‑
ural anticoagulants, AT, PC, and PS, not only in 
the Polish but also in the Slavic population. Twen‑
ty novel mutations were identified, all of which 
present in the heterozygous state.
The frequency of missense, nonsense, and 
splice ‑site mutations was similar for all 3 genes/
proteins. Missense mutations accounted for ap‑
proximately 50% of all the causal variants de‑
tected. Large rearrangements were found in 
the SERPINC1 and PROS1 genes. The detected 
mutations were located mainly in exon 2 and 7 
of the SERPINC1 gene, in exons 9, 7, and 5 of 
the PROC gene, and, with no exon ‑wise cluster‑
ing, across the whole PROS1 gene.
The newly detected p.Glu338* and the p.Val458_
Cys462del insGly mutations in the SERPINC1 
gene might impair protein synthesis/secretion 
and are most likely responsible for type I AT defi‑
ciency. Both variants were found also in the fam‑
ilies of the probands and were associated with 
VTE events. Similarly, another new variant, dele‑
tion of cytosine (c.948delC), may lead to produc‑
tion of truncated protein followed by a frameshift 
and the appearance of a premature stop codon in 
the SERPINC1 gene. In turn, the new p.Ala118Pro 
and the p.Gly125Cys variants both affect a very 
highly conserved residues in serpins located at he‑
lix B and may thus probably disturb the correct 
folding of AT. They may lead to the polymeriza‑
tion of the variant AT molecules and formation 
of disulphide ‑linked dimers present in the pa‑
tient’s plasma. These dimers may accumulate in‑
tracellularly in hepatocytes, affecting the synthe‑
sis of a wild ‑type AT and other inflammatory or 
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mutations at the same position, p.Gln226His 
and p.Gln226Leu, have been described in a new‑
born Spanish child with purpura fulminans and 
a Spanish patient screened for thrombophilia af‑
ter a DVT event, respectively.37,38 In the current 
study, the missense variant Gln226Leu in exon 7 
was also detected in a 49 ‑year ‑old male patient 
with DVT. Interestingly, the p.Cys106Arg vari‑
ant, previously described by us in a young Polish 
man with provoked DVT and PE,39 was detected 
in the current study in 3 other unrelated patients.
The  2 new mutations in the  PROS1 gene, 
p.Cys126Gly and the p.Cys241*, are located in 
the EGF ‑like‑1 and the EGF ‑like‑3 calcium bind‑
ing domains, respectively. It has been shown 
that most missense mutations identified with‑
in the EGF domains of PS affect protein stability, 
and cysteine residues are replaced in half of them.3 
It may be speculated that our novel p.Cys126Gly 
variant disrupts the protein structure, resulting 
in protein instability. The second newly identified 
mutation, p.Cys241*, might lead to the produc‑
tion of truncated protein. As PS is a principal co‑
factor of APC, its impaired secretion would limit 
the degradation of FVa and FVIIIa and enhance 
the procoagulant conditions.3,40 The last new vari‑
ant within the PROS1 gene, p.Gly489Arg, is locat‑
ed in the laminin ‑G‑like‑2 domain, suggested to 
comprise the C4BP ‑binding sites within segments 
408–434, 447–460, and 583 ‑635.41 Although this 
new variant is located outside the reported C4BP‑
‑binding sites, changing nonpolar and neutral gly‑
cine to polar and basic arginine might be expect‑
ed to influence the C4BP binding.
In 32% of AT ‑deficient, 6% of PC ‑deficient, and 
50% of PS ‑deficient individuals, no mutation in 
the respective genes was detected in the present 
study. It is possible that other genes on chromo‑
some 16q23 and 1q32 influence the PC and PS 
levels.16,42,43 PC activity can be modulated also 
by the genetic variants of EPCR44 and the poly‑
morphisms of the genes involved in the vitamin 
K ‑dependent γ ‑carboxylation reaction may also 
influence the activities of PC and PS.45 It should 
be also noted that for the measurement of AT ac‑
tivity, both the bovine thrombin‑ and the FXa 
inhibition ‑based tests, together with an antigen 
method, are advisable to be performed in pa‑
tients with suspected type II AT deficiency.46 For 
thrombin ‑based tests, a bovine thrombin should 
be preferred because a human thrombin reacts 
also with the heparin cofactor II, thus leading to 
overestimation of AT.47 On the other hand, false 
negative detection of all types of AT deficiencies 
with a FXa inhibition ‑based test, which may over‑
estimate AT activity levels, is also possible.
Interestingly, in the current study, no mu‑
tations were found in patients with AT activi‑
ty above 70%. This is in contrast to a study by 
Caspers et al,16 conducted in German patients, in 
whom the mutation detection rate remained at a 
level of about 70% for AT activities up to 75%.16 It 
seems that in our population, a genetic analysis of 
the SERPIC1 gene should be performed in patients 1
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with AT activity below 70%, where the mutation 
detection rate was 90%. However, due to a small 
sample size, this finding should be interpreted 
with caution. On the other hand, the study on 
the German population showed that the genetic 
analysis of the PROC gene should be performed 
in patients with PC activities below 70%, which 
worked fine also for our patients.16 Similarly, in 
our PS ‑deficient patients, no mutations were de‑
tected above 53% of PS activity, which is in line 
with the study by Caspers et al.16
The major study limitation was a relatively 
small sample size; however, we analyzed all eli‑
gible patients suspected of these types of throm‑
bophilia in our center. For the new mutations, 
functional studies should be performed in addi‑
tion to in silico predictions to prove their detri‑
mental effect.
In conclusion, we report here the largest cohort 
of Polish Slavic patients deficient in natural anti‑
coagulants, whom we evaluated for the causal ge‑
netic background. Several new Polish detrimen‑
tal mutations were detected mostly in patients 
with AT and PC deficiencies.
Supplementary material online Supplementary 
material is available with the online version of 
the article at www.pamw.pl.
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